Company news

Omeros Corporation news in 2026

Omeros Corporation's news releases, calls and decks from 2026, newest first.

View company

Omeros Corporation Reports Third Quarter 2026 Financial Results

November 16, 2026

Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026

November 10, 2026

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

October 16, 2026

Omeros Corporation Reports Second Quarter 2026 Financial Results

August 12, 2026

Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026

August 10, 2026

CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®

August 3, 2026

Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA

June 26, 2026

Omeros Corporation Reports First Quarter 2026 Financial Results

May 13, 2026

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

May 11, 2026

Omeros Corporation - CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA

April 17, 2026

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

April 16, 2026

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

March 30, 2026

Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

March 26, 2026

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

March 21, 2026

Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

February 16, 2026

Omeros Announces First Commercial Sales of YARTEMLEA®

January 27, 2026

Calls in 2026